Sequential to Host Inaugural London Summit on Ingredient Innovation
Artificial intelligence and multi-omics are dismantling traditional product development cycles, forcing a shift in how the beauty and biotech industries validate new molecules. On December 3, 2026, industry leaders will gather at The Mills Fabrica in London to address these emerging demands for scientific transparency and clinical proof.
The one-day forum, titled The Future of Next-Generation Ingredients & Validation, focuses on the intersection of bioengineering and market-ready clinical evidence. Sequential CEO Dr. Oliver Worsley intends to bridge the gap between AI-driven discovery and the rigorous verification standards now expected by global consumers.
Sessions will cover a breadth of topics including longevity research, healthy aging protocols, and bioengineered ingredient discovery. The program features a roster of experts, including keynote speaker Lieve Declercq of Proya Companies, alongside specialists from dsm-firmenich, Medik8, and The Honey Pot Company. Dr. Amir Jassim and Albert Dashi, Sequential’s co-founder, will also present findings on the role of clinical biomarkers in accelerating research across skin, scalp, and oral care sectors.
Comments (0)
No comments yet. Be the first!